WO1999034006A2 - Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih - Google Patents

Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih Download PDF

Info

Publication number
WO1999034006A2
WO1999034006A2 PCT/EP1998/008395 EP9808395W WO9934006A2 WO 1999034006 A2 WO1999034006 A2 WO 1999034006A2 EP 9808395 W EP9808395 W EP 9808395W WO 9934006 A2 WO9934006 A2 WO 9934006A2
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
lymphocytes
cell surface
cells
cell
Prior art date
Application number
PCT/EP1998/008395
Other languages
English (en)
Other versions
WO1999034006A3 (fr
Inventor
Claudio Bordignon
Original Assignee
Genera S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera S.P.A. filed Critical Genera S.P.A.
Priority to AU24159/99A priority Critical patent/AU2415999A/en
Publication of WO1999034006A2 publication Critical patent/WO1999034006A2/fr
Publication of WO1999034006A3 publication Critical patent/WO1999034006A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des cellules T CD4+ génétiquement modifiées pour exprimer un marqueur de surface cellulaire et capables de subir une infection par VIH dans des systèmes in vivo et in vitro. L'invention concerne également une méthode de sélection positive de cellules T CD4+, produisant une population totalement apte à une infection par VIH ou par un autre rétrovirus ou d'autres vecteurs rétroviraux, ce qui permet d'effectuer une transduction de cellules mononucléaires sanguines périphériques ou de cellules T CD4+.
PCT/EP1998/008395 1997-12-23 1998-12-22 Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih WO1999034006A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24159/99A AU2415999A (en) 1997-12-23 1998-12-22 A method for the positive selection of cd4+ t-lymphocytes transduced with anti-hiv genes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI972866 IT1297016B1 (it) 1997-12-23 1997-12-23 Processo di selezione di linfociti t cd4+ per la transduzione di geni anti-hiv
ITMI97A02866 1997-12-23

Publications (2)

Publication Number Publication Date
WO1999034006A2 true WO1999034006A2 (fr) 1999-07-08
WO1999034006A3 WO1999034006A3 (fr) 1999-09-02

Family

ID=11378447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/008395 WO1999034006A2 (fr) 1997-12-23 1998-12-22 Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih

Country Status (3)

Country Link
AU (1) AU2415999A (fr)
IT (1) IT1297016B1 (fr)
WO (1) WO1999034006A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021817A1 (fr) * 1999-09-24 2001-03-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phages recombinants capables de penetrer dans des cellules hotes via une interaction specifique avec un recepteur artificiel
EP1088892A1 (fr) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Phages récombinantes capable d'entrer dans des cellules hôtes par liaison avec un récepteur artificial

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
WO1996004386A1 (fr) * 1994-08-05 1996-02-15 Warner-Lambert Company Procede d'utilisation d'une integrase retrovirale negative transdominante dans le traitement d'infection retrovirale
EP0759471A1 (fr) * 1994-05-10 1997-02-26 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
WO1998017308A1 (fr) * 1996-10-25 1998-04-30 Immusol Incorporated Inhibition de l'infection par le vih par clivage de l'arn co-recepteur

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021806A1 (fr) * 1993-03-19 1994-09-29 Medical Research Council Systeme d'administration commande par des facteurs associes au vih et a la cellule
WO1995006723A1 (fr) * 1993-09-01 1995-03-09 Boehringer Mannheim Gmbh Procede de marquage de cellules eucariotes par utilisation d'un recepteur de surface cellulaire en tant que marqueur
EP0759471A1 (fr) * 1994-05-10 1997-02-26 Hisamitsu Pharmaceutical Co., Inc. Vecteur recombinant du virus de l'immunodeficience humaine et procede pour sa production
WO1996004386A1 (fr) * 1994-08-05 1996-02-15 Warner-Lambert Company Procede d'utilisation d'une integrase retrovirale negative transdominante dans le traitement d'infection retrovirale
WO1998017308A1 (fr) * 1996-10-25 1998-04-30 Immusol Incorporated Inhibition de l'infection par le vih par clivage de l'arn co-recepteur

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENATI, C. ET AL.: "Intracellular immunization for the treatment of HIV infection: a new rapid method to transduce and select primary human T-lymphocytes" GENE THERAPY, vol. 2, no. Suppl.1, 1995, pages S30-Abstr.111a, XP002105245 *
BONA, R. ET AL.: "Aberrant, noninfectious HIV-1 particles are released by chronically infected human T cells transduced with a retroviral vector expressing an interfering HIV-1 variant." GENE THERAPY, vol. 4, no. 10, October 1997, pages 1085-92, XP002105246 *
BORDIGNON C ET AL: "Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation" HUMAN GENE THERAPY, vol. 6, no. 6, June 1995, pages 813-819, XP002100641 *
MALIM M H ET AL: "FUNCTIONAL DISSECTION OF THE HIV-1 REV TRANS-ACTIVATOR-DERIVATION OF A TRANS-DOMINANT REPRESSOR OF REV FUNCTION" CELL, vol. 58, no. 1, 14 July 1989, pages 205-214, XP000050691 cited in the application *
TURCHETTO, L. ET AL.: "An approach to HIV gene therapy by transduction of multifunctional retroviral vectors in primary human T lymphocytes." JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS., vol. 11, no. 1/2, January 1997 - June 1997, pages 79-81, XP002105247 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021817A1 (fr) * 1999-09-24 2001-03-29 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Phages recombinants capables de penetrer dans des cellules hotes via une interaction specifique avec un recepteur artificiel
EP1088892A1 (fr) * 1999-09-24 2001-04-04 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Phages récombinantes capable d'entrer dans des cellules hôtes par liaison avec un récepteur artificial
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU770674B2 (en) * 1999-09-24 2004-02-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor

Also Published As

Publication number Publication date
AU2415999A (en) 1999-07-19
IT1297016B1 (it) 1999-08-03
ITMI972866A1 (it) 1999-06-23
WO1999034006A3 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
Sauter et al. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface.
Kalams et al. Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.
JP4409631B2 (ja) 高力価ウイルスの生産方法および哺乳動物細胞への効率のよいレトロウイルス媒介形質導入
Egelhofer et al. Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides
AU2017205637B2 (en) Compositions and libraries comprising recombinant T-cell receptors and methods of using recombinant T-cell receptors
Uckert et al. Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype
WO1989005349A1 (fr) Procede servant a combattre des infections virales
Masiero et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120
Chehimi et al. In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates
Shimizu et al. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein
Engels et al. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes
MORIKITA et al. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism
Mommaas et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer
MORGAN et al. Further evaluation of soluble CD4 as an anti-HIV type 1 gene therapy: demonstration of protection of primary human peripheral blood lymphocytes from infection by HIV type 1
Watanabe et al. A simian immunodeficiency virus envelope V3 cytotoxic T-lymphocyte epitope in rhesus monkeys and its restricting major histocompatibility complex class I molecule Mamu-A* 02
Kazanji et al. HTLV-I infection in squirrel monkeys (Saımiri sciureus) using autologous, homologous, or heterologous HTLV-I-transformed cell lines
US20110020901A1 (en) Methods of Making Viral Particles Having a Modified Cell Binding Activity and Uses Thereof
AU712415B2 (en) Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface
WO1999034006A2 (fr) Methode de selection positive de cellules t cd4+ transduites avec des genes anti-vih
Poznansky et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
Lodge et al. MuLV-based vectors pseudotyped with truncated HIV glycoproteins mediate specific gene transfer in CD4+ peripheral blood lymphocytes
Stitz et al. MLV-derived retroviral vectors selective for CD4-expressing cells and resistant to neutralization by sera from HIV-infected patients
AU2003242496B2 (en) Conjugate
Shieh The role of natural killer cells in simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) infection
WO1998037089A9 (fr) Peptides et proteines anti-vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase